- Antifungal Susceptibility to Amphotericin B, Fluconazole, Voriconazole, and Flucytosine in Candida Bloodstream Isolates from 15 Tertiary Hospitals in Korea
-
Jung SI, Shin JH, Choi HJ, Ju MY, Kim SH, Lee WG, Park YJ, Lee K, Korean Study Group for Candidemia
- KMID: 2434484
- Ann Lab Med.
- 2012 Nov;32(6):426-428.
The in vitro antifungal susceptibility of 636 Candida bloodstream isolates collected from 15 tertiary hospitals in Korea was determined using the Vitek-2 yeast susceptibility system (bioMerieux, France). Overall susceptibility rates... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
-
Kim DS, Na YJ, Kang MH, Yoon SY, Choi CW
- KMID: 2373811
- Korean J Intern Med.
- 2016 Mar;31(2):357-366.
- doi: 10.3904/kjim.2015.024
BACKGROUND/AIMS: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed,... -
- CITED
-
- Close
- SHARE
-
- Close
- In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values
-
Jang MJ, Shin JH, Lee WG, Kim MN, Lee K, Lee HS, Lee MK, Chang CL, Jang HC, Song ES, Kim SH, Shin MG, Suh SP, Ryang DW
- KMID: 1781321
- Ann Lab Med.
- 2013 May;33(3):167-173.
- doi: 10.3343/alm.2013.33.3.167
BACKGROUND: At present, the clinical breakpoints (CBPs) of both fluconazole and voriconazole are available only for 3 common Candida species in the Clinical and Laboratory Standards Institute (CLSI) and the... -
- CITED
-
- Close
- SHARE
-
- Close
